NCT00002290已完成不适用
A Multi-Center, Double-Blind Trial to Evaluate the Safety and Efficacy of Concurrent Retrovir (Zidovudine) and Zovirax (Acyclovir) Therapy in Patients With Early Symptomatic Human Immunodeficiency Virus (HIV) Infection
Glaxo Wellcome28 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 试验地点
- 28
研究概览
简要总结
This double-blind, placebo-controlled study is designed to determine the long-term safety and efficacy of concurrent oral Retrovir / Zovirax (AZT and ACV) therapy and oral AZT therapy alone, in the treatment of early symptomatic HIV infection. Efficacy will be evaluated by monitoring the incidence, severity, and time of development of opportunistic infections and other manifestations of advanced symptomatic HIV infection. The effects of the combination and single AZT therapy on immune function and viral replication will also be evaluated. Study participants will be monitored for evidence of toxicity or intolerance to concurrent AZT / ACV administration and AZT therapy alone.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have:
- •Early AIDS related complex (ARC).
- •Willingness to be followed by the original study center for the duration of the trial (96 weeks).
- •Ability to give informed consent.
- •Patients may have associated lymphadenopathy (lymph nodes greater than or equal to 1 cm in two noncontiguous areas).
排除标准
- •Co-existing Condition:
- •Patients with the following are excluded:
- •Concurrent neoplasms other than basal cell carcinoma of the skin or in situ carcinoma of the cervix.
- •Fever > 102 degrees F persisting for more than 14 consecutive days or more than 15 days in a 30-day interval, present at entry.
- •Severe malabsorption (evidenced by persistent diarrhea of greater than 4 weeks duration with = or > 6 loose stools per day accompanied by significant weight loss).
- •Concurrent Medication:
- •Acyclovir (ACV) therapy for chronic or recurrent herpes simplex.
- •Patients with an AIDS-defining indicator disease as outlined by the CDC surveillance definition for AIDS which includes opportunistic infections or neoplasms, HIV neurologic disease, AIDS dementia or the "wasting syndrome" are excluded.
- •Prior Medication:
- •Excluded within 4 weeks of study entry:
- •Any other experimental therapy.
- •Drugs which cause significant bone marrow suppression.
- •Rifampin or rifampin derivatives.
- •Cytolytic chemotherapy.
- •Drugs which cause significant nephrotoxicity or hepatotoxicity.
- •Immunomodulating agents, including steroids, interferon, Isoprinosine, immunoglobulin or interleukin
- •Excluded within 8 weeks of study entry:
- •Antiretroviral agents.
研究者
研究点 (28)
Loading locations...
相似试验
已完成
4 期
Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate)COPDNCT01488019Dey1,071
终止
2 期
Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1Complex Regional Pain Syndrome, Type INCT00109772Celgene Corporation184
已完成
2 期
Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar RadiculopathyRadiculopathyNCT00120120Celgene Corporation181
进行中（未招募）
3 期
Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)Pulmonary Emphysema in Alpha-1 PI DeficiencyNCT01983241Grifols Therapeutics LLC345
进行中（未招募）
2 期
RSYR for Fatigue Reduction in Cancer Fatigue Caused by ChemotherapyCancer-related Problem/ConditionNCT05229029Peking University Cancer Hospital & Institute196